Cortagen

Cortagen is a synthetic tetrapeptide, Ala-Glu-Asp-Pro, developed from amino-acid analysis of a natural brain cortex peptide preparation. The literature is mostly older, preclinical, and mechanistic. One mouse microarray study reported that short-course Cortagen injections altered cardiac transcript expression. A rat chronic brain ischemia model reported behavioral recovery and improved oxidative-stress markers after cortexin or cortagen treatment, but this remains animal evidence. An in vitro splenocyte study found Cortagen had a less pronounced effect than Vilon or Epithalon on interleukin-2 mRNA synthesis. Cortagen should be described as a peptide bioregulator studied in animal and cell models, not as clinically proven for brain injury, ischemia, cognition, immune support, or anti-aging.

Gene-Expression Research

Cortagen treatment changed cardiac gene-expression profiles in a mouse microarray study, supporting research interest in peptide-associated transcriptional effects ^[1].

Brain-Ischemia Model

In a rat chronic brain ischemia model, cortagen and cortexin were reported to improve disturbed behavior and oxidative-stress markers ^[2].

Immune-Cell Model

Cortagen activated interleukin-2 mRNA synthesis in mouse splenocytes in vitro, though less strongly than comparator peptides ^[3].

Preclinical Evidence Limits

The available Cortagen evidence is mostly animal and in vitro; no robust human clinical safety dataset or regulatory label was found ^[1][2][3].

Translation Caveat

Gene-expression and immune-transcription observations are not proof of therapeutic safety or efficacy in people ^[1][3].